Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2011
04/14/2011WO2011044501A2 Antibacterial aminoglycoside analogs
04/14/2011WO2011044499A2 Enterotoxigenic e. coli fusion protein vaccines
04/14/2011WO2011044498A1 Antibacterial aminoglycoside analogs
04/14/2011WO2011044481A1 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
04/14/2011WO2011044434A2 A composition and a method of treating cns disorders and hyperpigmentation
04/14/2011WO2011044415A1 Combination
04/14/2011WO2011044414A1 Combination
04/14/2011WO2011044394A1 Purine derivatives useful as hsp90 inhibitors
04/14/2011WO2011044375A2 Apogossypolone derivatives as anticancer agents
04/14/2011WO2011044370A1 Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
04/14/2011WO2011044366A1 Blocking defects in molecular sieve membranes with cyclodextrin
04/14/2011WO2011044331A1 Androgen treatment in females
04/14/2011WO2011044307A1 Phenyloxadiazole derivatives as pgds inhibitors
04/14/2011WO2011044264A2 Pyrrolopyrazoles for treating cns disorders
04/14/2011WO2011044230A2 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
04/14/2011WO2011044229A1 2h-pyrrol-5-amine derivatives as alpha adrenergic receptor modulators
04/14/2011WO2011044225A1 Modulators of g protein-coupled receptor 88
04/14/2011WO2011044222A1 Antimicrobial compounds
04/14/2011WO2011044213A1 Synergistic fungicidal mixtures for fungal control in cereals
04/14/2011WO2011044212A1 Modulators of g protein-coupled receptor 88
04/14/2011WO2011044207A2 Compositions containing a high concentration of polar sphingolipid(s)
04/14/2011WO2011044197A1 Spirocyclic compounds as modulators of chemokine receptor activity
04/14/2011WO2011044195A1 Modulators of g protein-coupled receptor 88
04/14/2011WO2011044187A1 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
04/14/2011WO2011044184A1 Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
04/14/2011WO2011044181A1 Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
04/14/2011WO2011044167A1 Methods of treating diseases with proanthocyanidin oligomers such as crofelemer
04/14/2011WO2011044157A1 Heterocyclic compounds useful as pdk1 inhibitors
04/14/2011WO2011044141A1 Fatty acid fibrate derivatives and their uses
04/14/2011WO2011044136A1 Fatty acid acipimox derivatives and their uses
04/14/2011WO2011044105A1 Treatment with cholinergic agonists
04/14/2011WO2011044073A1 Pyrrolidine gpr40 modulators
04/14/2011WO2011044072A1 Combination of raf-265 and an activator of ampk for use in the treatment of a proliferative disease
04/14/2011WO2011044057A1 Sulfonamido pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
04/14/2011WO2011044034A1 Carrageenan-containing aqueous antimicrobial compositions
04/14/2011WO2011044019A1 (R)-1-(4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY)PROPAN-2-OL METABOLITES
04/14/2011WO2011044001A1 Compounds and compositions as modulators of gpr119 activity
04/14/2011WO2011043994A1 Inhibitors of fatty acid binding protein (fabp)
04/14/2011WO2011043962A2 Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof
04/14/2011WO2011043954A1 Novel trpa1 antagonists
04/14/2011WO2011043914A1 Diuretics
04/14/2011WO2011043876A1 Synergistic fungicidal composition containing 5-fluorocytosine for fungal control in cereals
04/14/2011WO2011043827A1 Methods for preventing or treating sarcopenia and muscle atrophy in animals
04/14/2011WO2011043809A2 Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling
04/14/2011WO2011043788A2 Daptomycin for multiple sclerosis
04/14/2011WO2011043739A1 Methods and compositions for maintenance of a functional wound
04/14/2011WO2011043690A1 Method for producing biocidal polyguanidine, and biocidal polyguanidine
04/14/2011WO2011043670A1 Amino acid composition with improved dispersibility
04/14/2011WO2011043647A1 Amino acid composition with improved dispersibility
04/14/2011WO2011043631A2 Pharmaceutical composition for preventing and treating cold, containing reynoutria elliptica extract, fraction thereof or stilbene-based compound
04/14/2011WO2011043630A2 Composition for preventing and treating obesity diseases containing highly water-soluble 2-hydroxypropyl-β-cyclodextrin as active ingredient
04/14/2011WO2011043568A2 Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
04/14/2011WO2011043532A1 Lipid nanoparticles for oral administration, and method for preparing same
04/14/2011WO2011043480A1 Homocysteine synthase inhibitor
04/14/2011WO2011043479A1 Therapeutic agent for cerebral infarction
04/14/2011WO2011043456A1 Halogenated alkylsulfonamide derivative
04/14/2011WO2011043455A1 Orally administrable liquid formulation containing acetaminophen
04/14/2011WO2011043453A1 Activator for peroxisome proliferator activated receptor
04/14/2011WO2011043435A1 Therapeutic agent for influenza virus infectious diseases
04/14/2011WO2011043397A1 Anti-influenza virus agent
04/14/2011WO2011043387A1 Pyrazoloxazole compound
04/14/2011WO2011043381A1 Pyrazolothiazole compound
04/14/2011WO2011043371A1 Oxazole compound
04/14/2011WO2011043369A1 Water-soluble porphyrin and process for production thereof
04/14/2011WO2011043359A1 Pharmaceutical product containing aromatic heterocyclic compound
04/14/2011WO2011043237A1 Agent for ameliorating type-2 diabetes, and food or beverage containing same
04/14/2011WO2011043212A1 Ceramide production enhancer and moisturizing agent
04/14/2011WO2011042890A2 Use of phenolic compounds for protein deglycolysation
04/14/2011WO2011042877A1 Use of celivarone for the preparation of a medicament for use in the prevention of implantable cardioverter defibrillator interventions or death
04/14/2011WO2011042872A1 Use of a dna replication inhibitor for treating neurodegenerative diseases caused by polyglutamine expansion
04/14/2011WO2011042860A2 New derivatives of thieno[2,3-b]pyridine and 5,6,7,8-tetrahydrothieno[2,3-b]quinoline in particular useful in the treatment of malaria
04/14/2011WO2011042812A1 Use of rasagiline for the treatment of progressive supranuclear palsy
04/14/2011WO2011042798A1 Pyrazoles derivatives modulators of calcium release -activated calcium channel and methods for treatment of non- small cell lung cancer
04/14/2011WO2011042797A1 Pyrazole derivatives as modulators of calcium release -activated calcium channel
04/14/2011WO2011042793A1 Stabilized pharmaceutical composition comprising gabapentin with minimum levels of pharmaceutically acceptable inert excipients
04/14/2011WO2011042765A1 Inorganic salt complexes of vildagliptin
04/14/2011WO2011042701A1 Compositions for the prevention or treatment of migraine
04/14/2011WO2011042654A1 P-glycoprotein-specific non-competitive peptide and peptidomimetic modulators
04/14/2011WO2011042560A1 Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
04/14/2011WO2011042497A1 Pyrrolo [3,2 -e] [1,2,4] triazolo [1,5-a] pyrimidines derivatives as inhibitors of microglia activation
04/14/2011WO2011042496A1 Pyrrolo [3, 2 -e] [1,2,4] triazolo [1,5 -a] pyrimidines derivatives as inhibitors of microglia activation
04/14/2011WO2011042485A1 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
04/14/2011WO2011042482A1 Polyphenols for use in the treatment of cancer
04/14/2011WO2011042477A1 Substituted pyrroles and imidazoles as estrogen receptor ligands
04/14/2011WO2011042475A1 Substituted pyrazoles as estrogen receptor ligands
04/14/2011WO2011042474A1 Novel estrogen receptor ligands
04/14/2011WO2011042473A2 Novel estrogen receptor ligands
04/14/2011WO2011042466A1 Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
04/14/2011WO2011042465A1 Sulfonamides for the prevention of diabetes
04/14/2011WO2011042463A2 Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
04/14/2011WO2011042453A1 Subcutaneous paliperidone composition
04/14/2011WO2011042420A1 Delivery system for sustained release of a calcium -channel blocking agent
04/14/2011WO2011042399A1 Bicyclic heterocycles and their use as ccr2 receptor antagonists
04/14/2011WO2011042368A1 Fluoro-substituted 3,5-dicyano-4-(1h-indazol-5-yl)-2,6-dimethyl-1,4-dihydropyridine derivatives and methods of use thereof
04/14/2011WO2011042367A1 Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof
04/14/2011WO2011042343A1 Indane-amine derivatives, their preparation and use as medicaments
04/14/2011WO2011042302A1 Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments
04/14/2011WO2011042156A1 Pharmaceutical compositions comprising rivaroxaban
04/14/2011WO2011042145A1 Wnt pathway antagonists
04/14/2011WO2011042086A1 Use of heterocyclically substituted 1,2,4-triazine diones